Xenetic Biosciences

Company snapshot

Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. X

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Xenetic Biosciences. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Xenetic Biosciences.

1. Jun 8, 2026 Clinical update

   Sodium Cridanimod — Phase 2

2. Jan 29, 2019 Patent grant

   Compositions and methods for administering insulin or insulin-like protein to the brain

View all clinical trial activity →

• What is Xenetic Biosciences?

  Xenetic Biosciences is a pharma organization headquartered in Framingham, USA. It trades on NYSE under ticker XBIO. Primary therapeutic focus areas include Endometrial Cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 1 patent record(s) to this entity fro

• Is Xenetic Biosciences publicly traded?

  Yes. Xenetic Biosciences is listed with ticker XBIO on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Xenetic Biosciences develop or market?

  We link 1 drug profile(s) where Xenetic Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/xenetic-biosciences#company-drugs.

• What are the latest developments for Xenetic Biosciences?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Xenetic Biosciences focus on?

  Xenetic Biosciences focuses on Endometrial Cancer based on our analysis of their pipeline programs and drug development activities.